Diabetes Mellitus em cães e suas complicações

Diabetes mellitus is one of the most common endocrinopathies among dogs characterized by hyperglycemia and if not treated properly can be fatal. It occurs by an absolute or relative insulin deficiency, which alters the metabolism of carbohydrates, lipids and proteins Complications such as cataracts, recurrent infections, pancreatitis and ketoacidosis can arise with the development of the disease. Recognizing these will help the diagnosis, once in some dogs it is not always detected the classical signs of polyuria, polydipsia, polyphagia and weight loss

Efeito do diabetes sobre o crescimento puberal da próstata de rato: avaliação hormonal, imunocitoquímica e bioquímica

Adequate testosterone levels are necessary for the development, growth and maintenance of the male reproductive system. Testosterone deficiency is common in men with diabetes in whom it may contribute to impaired performance, with consequent reduction of the activity of the androgen regulated organs, such as the prostate. However, little attention has been given to the plasma dihydrotestosterone (DHT) level, the most potent androgen, nor to the expression of the androgen receptor (AR), insulin-like growth factor type I (IGF-1) and receptor (IGF-1R) in target tissues. Here, we investigated the effect of type I diabetes mellitus on DHT plasma levels and on prostate AR, IGF-1 and IGF-1R expression during rat pubertal growth. Diabetes was induced in prepubertal male rats through administration of streptozotocin (STZ; 40 mg/kg). Diabetic, diabetic treated with insulin, and age-matched control animals were killed by overdoses of pentobarbital. The ventral prostatic lobe (VP) was dissected, weighed and processed for immunohistochemistry for AR, IGF-1 e IGF-1R; plasma T and DHT levels were also determined. Hyperglycemia at puberty reduced VP weight gain to about 50% and plasma T level to about 80% of the control levels. In contrast there were no changes in plasma DHT levels. Insulin replacement restored the VP weight gain, but not the plasma T levels, which remained 90% below the ones of controls. Immunohistochemistry showed that AR, IGF-1 and IGF-1R expression in the prostate epithelial cells did not change with hyperglycemia or insulin replacement. Thus, the AR expression in the prostate epithelial cells appears to be regulated by DHT, and to a minor extent it also controls glandular growth

Cetoacidose diabética em pequenos animais

Diabetic ketoacidosis (DKA) is one of the most serious complications of Diabetes Mellitus (DM) in small animals (SILVA, 2006). It is an acute metabolic disorder, potentially fatal, both in humans and in dogs and cats with DM (BRUYETTE, 1997), being related, mostly, to insulin-dependent diabetics (CHASTAIN, 1981; HUME et al., 2006). DKA is a medical emergency characterized by extreme metabolic abnormalities, including hyperglycemia, metabolic acidosis, ketonemia, dehydration and electrolyte loss (MACINTIRE, 2006) and its diagnosis may be established basically by the detection of ketonuria and metabolic acidosis (NELSON, 2009). The primary purposes of the treatment of DKA are intravascular volume restoration, dehydration, acid-base and electrolyte’s imbalances correction and blood glucose concentration reduction (BOYSEN, 2008). The treatment’s success depends of the clinical status at the time of diagnosis and of the introduction of an appropriate therapy to the conditions of each patient (CHASTAIN, 1981)

Terapia do diabetes mellitus em cães

Diabetes Mellitus is caracterized by a disturbance on endocrine pâncreas with reduction in serum levels of insulin. The deficiency or absence of insulin promotes alterations in the metabolism of carbohydrates, lipidis and proteins. The most common clinical signs of disease are polyuria, polydipsia, polyphagia and loses of weight. The diagnosis is made based on clinical symptoms, with laboratory confirmation through persistent hyperglycemia on fasting and glycosuria. Treatment includes insulin therapy, diet, exercise and oral hypoglycemic agents in an attempt to reverse the catabolic effects associated with deficiency or antagonism of insulin and restore normal homeostasis of the metabolism of proteins, lipids and carbohydrates

IL-10 e TNF-α no sangue materno e nas placentas de gestações complicadas por diabete ou hiperglicemia gestacional leve - correlação com controle glicêmico e resultados perinatais

Objective - At evaluating the IL-10 production in maternal blood and placenta and correlate them with perinatal outcomes in pregnancies complicated by hyperglycemia, or with risk to developing it, differentiated by the glycemic mean (GM < or ≥ 100mg/dL). Method- 186 pregnant women were distributed into groups GM < 100 mg/dL and GM ≥ 100 mg/dL. We evaluated the GM, HbA1c levels, maternal and placental IL-10 and TNF-α and the correlation between placental cytokines and perinatal outcomes. Results - In maternal blood, the lower concentrations of IL-10 (1.01 ± 0.87 vs. 3.08 ± 5.57 pg / mL, p = 0.0019) were observed in GM ≥ 100 mg / dL group. Placental IL-10 was directly correlated with hemoglobin levels (r = 0.63, p = 0.02) and insulin (r = 0.78, p = 0.01) from umbilical cord and with Apgar scores 1 (r = 0.53, p = 0.0095) and Apgar 5 (r = 0.69, p = 0.0003). Conclusion - GM ≥ 100mg/dL was associated with decreased of maternal IL-10. Placental IL-10 was similar in both groups and correlated directly with hemoglobin and insulin and with Apgar scores of 1st. and 5th. minutes

The influence of different implant surfaces on osseointegration in diabetes: a systematic review of the literature

AIM: The aim of this study was to evaluate, through a systematic review of the literature, the effects of different implant surface modifications on osseointegration in diabetic subjects. METHODS: A search was performed of the PubMed database, using a combination of the following keywords: “Implant surface” OR “Dental implants” AND “Diabetes” OR “Hyperglycemia”. Papers published in English between January 1960 and November 2013 were selected. All experimental models were considered in this search, but case reports and in vitro studies were excluded from this review. RESULTS: The initial search identified 182 articles. After reading the titles and abstracts, 39 articles were selected for full reading. Finally, 4 papers were selected after evaluation of all the papers, and these papers are discussed in this review. Due to the methodological heterogeneity of the selected studies, it was not possible to perform a meta-analysis of the data. CONCLUSION: It can be concluded that although the benefits of surface modifications present in individuals with diabetes have biological plausibility, there is little evidence of the benefits of these modifications.

Control of respiratory and cardiovascular functions by leptin

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeitos do treinamento resistido na síndrome metabólica: uma revisão sistemática com meta-análise e um ensaio clínico randomizado

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Aspectos da fisiopatologia da sepse em Piaractus mesopotamicus induzida por Aeromonas hydrophila

Pós-graduação em Medicina Veterinária - FCAV

Efeitos preventivos do exercício físico na expressão da miostatina em ratos tratados com Dexametasona

Muscle atrophy is always associated with Dexamethasone (Dexa) treatment, however the mechanisms are not completely understood. This study investigated the effects of Dexa on myostatin and p70S6K protein expression and if previous exercise training (T) can attenuate these effects. Eighty rats were distributed into 4 groups: sedentary control (SC), sedentary treated with Dexa (SD; 0,5 mg/kg per day, i.p., 10 days), trained control (TC) and trained treated with Dexa (TD) and underwent a training period where they were either submitted to a running protocol (60% of physical capacity, 5 days/week for 8 weeks) or kept sedentary. After T period, animals underwent Dexa treatment concomitant with training. Western Blot was performed to identify myostatin and p70S6k protein expression in the tibialis anterior (TA) and soleus (SOL) muscle. Ten days of Dexa treatment increased fasting glucose (SD=+62%), however previous T attenuated this increase (TD=+20%, p<0.05). Dexa determined significant decrease in body weight in TD (-22%) and SD (-25%), followed by TA weight reduction in SD (-23%) and TD (-20%). Previous training could not avoid these decreases. Myostatin protein expression was not altered by dexa treatment or training in TA muscle but in SOL muscle it was significantly modified after T, regardless of treatment (TC=+%23 and TD=+25) compared with their respective controls. The protein p70S6K was not modified neither by dexa nor training in any of the analyzed muscle or condition. The results of this study allowed us to conclude that previous training attenuates the hyperglycemia induced by Dexa, however it did not prevent the body or muscle weight reductions. Even in the presence of muscle atrophy, the expression of myostatin and p70S6K do not justify the mechanisms of muscle loss induced by Dexa, which suggests that other catabolic or anabolic proteins could be involved in the process of muscle atrophy after 10 days of treatment with Dexa

Alloxan-Induced Diabetes Causes Morphological and Ultrastructural Changes in Rat Liver that Resemble the Natural History of Chronic Fatty Liver Disease in Humans

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Oxidative DNA damage in diabetic and mild gestational hyperglycemic pregnant women

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Oxidative dtress status and placental implications in diabetic rats undergoing swimming exercise after embryonic implantation

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats

Exenatide extended-release (ER) is a microencapsulated formulation of the glucagon-like peptide 1-receptor agonist exenatide: It has a protracted pharmacokinetic profile that allows a once-weekly injection with comparable efficacy to insulin with an improved safety profile in type II diabetic people. Here, we studied the pharmacology of exenatide ER in 6 healthy cats. A single subcutaneous injection of exenatide ER (0.13 mg/kg) was administered on day 0. Exenatide concentrations were measured for 12 wk. A hyperglycemic clamp (target = 225 mg/dL) was performed on days 7 (clamp I) and 21 (clamp II) with measurements of insulin and glucagon concentrations. Glucose tolerance was defined as the amount of glucose required to maintain hyperglycemia during the clamp. Continuous glucose monitoring was performed on weeks 0, 2, and 6 after injection. Plasma concentrations of exenatide peaked at 1 h and 4 wk after injection. Comparing clamp I with clamp II, fasting blood glucose decreased (mean standard deviation = 11 8 mg/dL, P = 0.02), glucose tolerance improved (median [range] +33% 14%-138%], P = 0.04), insulin concentrations increased (+36.5% [-9.9% to 274.1%], P = 0.02), and glucagon concentrations decreased (-4.7% [0%-12.1%], P = 0.005). Compared with preinjection values on continuous glucose monitoring, glucose concentrations decreased and the frequency of readings <50 mg/dL increased at 2 and 6 wk after injection of exenatide ER. This did not correspond to clinical hypoglycemia. No other side effects were observed throughout the study. Exenatide ER was safe and effective in improving glucose tolerance 3 wk after a single injection. Further evaluation is needed to determine its safety, efficacy, and duration of action in diabetic cats. (C) 2015 Elsevier Inc. All rights reserved.

Regulation of hepatic TRB3/Akt interaction induced by physical exercise and its effect on the hepatic glucose production in an insulin resistance state

To maintain euglycemia in healthy organisms, hepatic glucose production is increased during fasting and decreased during the postprandial period. This whole process is supported by insulin levels. These responses are associated with the insulin signaling pathway and the reduction in the activity of key gluconeogenic enzymes, resulting in a decrease of hepatic glucose production. On the other hand, defects in the liver insulin signaling pathway might promote inadequate suppression of gluconeogenesis, leading to hyperglycemia during fasting and after meals. The hepatocyte nuclear factor 4, the transcription cofactor PGC1-α, and the transcription factor Foxo1 have fundamental roles in regulating gluconeogenesis. The loss of insulin action is associated with the production of pro-inflammatory biomolecules in obesity conditions. Among the molecular mechanisms involved, we emphasize in this review the participation of TRB3 protein (a mammalian homolog of Drosophila tribbles), which is able to inhibit Akt activity and, thereby, maintain Foxo1 activity in the nucleus of hepatocytes, inducing hyperglycemia. In contrast, physical exercise has been shown as an important tool to reduce insulin resistance in the liver by reducing the inflammatory process, including the inhibition of TRB3 and, therefore, suppressing gluconeogenesis. The understanding of these new mechanisms by which physical exercise regulates glucose homeostasis has critical importance for the understanding and prevention of diabetes.